Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Oyewale O. Abidoye
Observed names:
O Abidoye,
O. Abidoye,
O. O. Abidoye,
Oyewale Abidoye,
Oyewale O Abidoye
Institutions:
Mayo Clinic,
Mayo Clinic Comprehensive Cancer Center (Arizona)
Observed institutions:
Mayo Clinic,
Genentech,
Medical College of Wisconsin,
University of Chicago,
University of Chicago Medical Center,
Scripps Memorial Hospital,
National Cancer Institute,
Research Advocacy Network,
Mayo Clinic Comprehensive Cancer Center (Arizona)
show all 9
OpenAlex ID:
A5084458085
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
2016
·
Jonathan E Rosenberg
, Jean Hoffman-Censits
, et al.
·
The Lancet
·
3,645
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
2016
·
Arjun V Balar
, Matthew D Galsky
, et al.
·
The Lancet
·
2,189
Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma
2016
·
M Stroh
, H Winter
, et al.
·
Clinical Pharmacology & Therapeutics
·
159
MET as a target for treatment of chest tumors
2008
·
Nicole A. Cipriani
, Oyewale O. Abidoye
, et al.
·
Lung Cancer
·
120
IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
2016
·
Jean H. Hoffman-Censits
, Petros Grivas
, et al.
·
Journal of Clinical Oncology
·
83
A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
2006
·
O. O. Abidoye
, E. E. Cohen
, et al.
·
Journal of Clinical Oncology
·
79
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).
2015
·
Daniel Peter Petrylak
, Thomas Powles
, et al.
·
Journal of Clinical Oncology
·
63
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
2013
·
Hope S. Rugo
, Adam M. Brufsky
, et al.
·
Breast Cancer Research and Treatment
·
52
PDF
Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System
2015
·
Nazia Rashid
, Han A. Koh
, et al.
·
Journal of Managed Care & Specialty Pharmacy
·
51
PDF
Lung carcinoma in African Americans
2007
·
Oyewale Abidoye
, Mark K Ferguson
, et al.
·
Nature Clinical Practice Oncology
·
45
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
2016
·
Arjun Vasant Balar
, Matt D. Galsky
, et al.
·
Journal of Clinical Oncology
·
31
Review of Clinic Trials: Agents Targeting c-Met
2007
·
Oyewale Abidoye
, Nadh Murukurthy
, et al.
·
Reviews on Recent Clinical Trials
·
31
Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study
2016
·
Y. Loriot
, J.E. Rosenberg
, et al.
·
Annals of Oncology
·
24
EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
2008
·
Martin Sattler
, Oyewale Abidoye
, et al.
·
The Scientific World JOURNAL
·
22
PDF
Neo‐adjuvant Capecitabine Chemotherapy in Women with Newly Diagnosed Locally Advanced Breast Cancer in a Resource‐poor Setting (Nigeria): Efficacy and Safety in a Phase II Feasibility Study
2013
·
Olukayode A. Arowolo
, Uchenna O. Njiaju
, et al.
·
The Breast Journal
·
19
PDF
Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC).
2016
·
Robert Dreicer
, Jean H. Hoffman-Censits
, et al.
·
Journal of Clinical Oncology
·
15
21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)
2015
·
J. Rosenberg
, D. Petrylak
, et al.
·
European Journal of Cancer
·
14
Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden
2014
·
Mark S. Walker
, Anthony S. Masaquel
, et al.
·
Breast Cancer Research and Treatment
·
10
Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.
2017
·
Jose Luis Perez-Gracia
, Yohann Loriot
, et al.
·
Journal of Clinical Oncology
·
7
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
2016
·
Arjun Vasant Balar
, Matt D. Galsky
, et al.
·
Journal of Clinical Oncology
·
7
The Impact Of Non-Muscle Invasive Bladder Cancer: Qualitative Research With Patients
2015
·
M Clark
, NI Harris
, et al.
·
Value in Health
·
3
Impacts of toxicity on patient treatment choices for metastatic breast cancer.
2012
·
Carol B. White
, Mary Lou Smith
, et al.
·
Journal of Clinical Oncology
·
3
Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study.
2013
·
Denise Aysel Yardley
, Ian E. Krop
, et al.
·
Journal of Clinical Oncology
·
1
Real-world symptom burden and early treatment discontinuation in first-line metastatic breast cancer (MBC).
2013
·
Mark S. Walker
, Anthony Masaquel
, et al.
·
Journal of Clinical Oncology
·
1
Abstract P6-09-11: Examining patient treatment choices involving efficacy, toxicity, and cost tradeoffs in the metastatic breast cancer setting
2012
·
CB White
, ML Smith
, et al.
·
Cancer Research
·
1
Show more works
View as search
Works count:
35
Citation count:
6,676
H-index:
15
I10-index:
18
Year
Topic
Type